9:00 am Chair’s Opening Remarks

9:10 am Industry Leader’s Fireside Chat

  • Adrian Rawcliffe Chief Executive Officer, Adaptimmune
  • Stanley Frankel Senior Vice President, Global Drug Development, Therapeutic Area Head, Cell Therapy, Bristol-Myers Squibb
  • Martina Sersch Chief Medical Officer, Gracell Biotechnologies
  • Usman Azam Chief Executive Officer, Tmunity Therapeutics

10:00 am Presentation on Behalf of Terumo BCT

  • Bruce Levine Cancer Gene Therapy & Founding Director, Clinical Cell & Vaccine Production Facility, University of Pennsylvania

10:30 am Virtual Speed Networking

DISCOVERY

Developing Safe, Controllable CAR-TCR Product

11:30 am Pharmacologic Control for Enhanced Efficacy Against Solid Tumors

  • Steve Shamah SVP, Scientific Affairs & Technology, Obsidian Therapeutics

11:50 am Approaches to Reduce Toxicities Associated with CAR T Cell Intervention

  • John Rossi Senior Director, Translational Medicine, Kite, a Gilead Company

12:10 pm Novel CellGenix® T Cell Medium (CellGenix® TCM)

12:30 pm Live Q&A with Your Expert Speakers

  • Steve Shamah SVP, Scientific Affairs & Technology, Obsidian Therapeutics
  • John Rossi Senior Director, Translational Medicine, Kite, a Gilead Company
  • Sebastien Warth Senior Scientist, CellGenix

12:45 pm Refreshment Break & Tech Slam

Innovative Target Identification to Define Clinically Beneficial & Safe Targets

1:45 pm TScan, a Whole Genome, Unbiased Approach to Cancer Target Discovery

2:05 pm Driving Novel Tumor Targeting with Neoantigen-directed Therapies

2:25 pm TCR-T Therapies for Solid Tumors Using Multiple Novel Targets

2:45 pm Program Partner Presentation

3:05 pm Live Q&A with Your Expert Speakers

3:25 pm Refreshment Break

3:40 pm Data-Driven Approaches for Consistent Apheresis

  • Hassan Saleem Head of Global Apheresis Operations, bluebird bio
  • Lee Clough Tissue Operations Expert, Apheresis Operations Europe, Novartis
  • Rocky Billups Vice President, Operations, Sarah Cannon Blood Cancer Network HCA
  • Augustus Kilgore Sr. Global Training Consultant, Cell & Gene Therapy, Terumo BCT

4:40 pm Refreshment Break

Novel Construct Design to Tackle the Solid Tumor Microenvironment

4:55 pm Multi-Antigen Targeting for Diverse Cancers – Keep it Simple!

Next Generation Gene Engineering Approaches for Enhanced Specificity

5:15 pm Co-Stimulatory Switch Receptors Imbue TCR-Ts with Improved Functional Capacities

5:35 pm Live Q&A with Your Expert Speakers

5:45 pm Implementation of Next Generation Gene Editing for Allogeneic T Cell Therapeutics

6:05 pm iPSC-derived Targeted NK Cells for Hematologic Cancer Treatment

6:25 pm Live Q&A with Your Expert Speakers

6:35 pm Chair’s Closing Remarks